Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Piper Sandler

Piper Sandler began coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report report published on Friday morning, MarketBeat reports. The brokerage issued an overweight rating and a $48.00 price objective on the stock.

A number of other analysts have also recently commented on AVTX. Wedbush initiated coverage on Avalo Therapeutics in a research report on Friday, February 21st. They set an “outperform” rating and a $18.00 price objective for the company. BTIG Research initiated coverage on Avalo Therapeutics in a research report on Thursday, December 19th. They set a “buy” rating and a $40.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Avalo Therapeutics has a consensus rating of “Buy” and an average price target of $35.33.

Avalo Therapeutics Stock Performance

AVTX stock opened at $7.31 on Friday. Avalo Therapeutics has a 1-year low of $4.28 and a 1-year high of $34.46. The business has a fifty day moving average price of $7.60 and a 200-day moving average price of $9.27.

Institutional Trading of Avalo Therapeutics

Hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC grew its holdings in Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after purchasing an additional 3,754 shares during the period. Marshall Wace LLP bought a new position in shares of Avalo Therapeutics in the fourth quarter worth about $114,000. Walleye Capital LLC bought a new position in shares of Avalo Therapeutics in the fourth quarter worth about $145,000. Northern Trust Corp bought a new position in shares of Avalo Therapeutics in the fourth quarter worth about $168,000. Finally, Bank of Montreal Can bought a new position in shares of Avalo Therapeutics in the fourth quarter worth about $446,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.